Sound Pharma Initiates Enrollment in Pivotal Phase 3 Clinical Trial of SPI-1005 for the Treatment of Hearing Loss and Tinnitus in Meniere ’s Disease

July 28, 2022 -- Sound Pharmaceuticals is pleased to announce that it has enrolled the first patient in its Phase 3 clinical trial involving SPI-1005 for the Treatment of Meniere’s Disease (STOPMD-3). Additionally, this marks the first Phase...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials